Hims & Hers Health Inc SEC Filings

Irene Becklund, an officer of Hims & Hers Health, Inc. (HIMS), reported a sale of Class A common stock on 09/17/2025. The Form 4 shows she disposed of 8,410 shares at a price of $50.50 per share under transaction code S(1). After the sale, she beneficially owned 1,418 shares. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted August 7, 2024. The Form 4 was signed by Kimberly Mather as attorney-in-fact for Irene Becklund on 09/19/2025.

Michael Chi, Chief Commercial Officer of Hims & Hers Health, Inc. (HIMS), reported an insider sale. On 09/17/2025 he disposed of 13,749 shares of Class A common stock at $50.50 per share, leaving him with 297,139 shares beneficially owned after the transaction. The Form 4 states the sales were executed under a Rule 10b5-1 trading plan adopted by Mr. Chi on March 4, 2025. The filing is signed by Kimberly Mather as attorney-in-fact for Michael Chi on 09/19/2025. The document contains no additional financial results or commentary.

Andrew Dudum, a director, 10% owner and CEO-related reporting person of Hims & Hers Health, Inc. (HIMS), sold 65,110 shares of Class A common stock on 09/17/2025 under a Rule 10b5-1 trading plan adopted August 28, 2024. The sales generated an average weighted price of $50.5745 per share, with individual sale prices ranging from $50.06 to $50.94. After the reported transactions, the reporting person beneficially owned 95,315 shares of Class A common stock. The Form 4 was signed by an attorney-in-fact on 09/19/2025 and includes an undertaking to provide share-by-share price details upon request.

Patrick Harrison Carroll, Chief Medical Officer and director of Hims & Hers Health, Inc. (HIMS), reported transactions dated 09/15/2025 on Form 4. He was granted 16,521 RSUs that convert one-for-one into Class A common stock and additional RSU awards listed in the filing totaling 16,521 + 8,148 + 4,840 + 3,533 units across entries. The issuer withheld 6,500 shares to satisfy tax withholding at a reported price of $53.96, reducing reported Class A common stock beneficial ownership from 186,461 to 179,961 following the withholding. The RSUs are subject to service-based vesting schedules, generally over four years with quarterly vesting dates specified in the filing.

The filing is a reporting of equity awards and related withholding; it documents grant mechanics, vesting schedules, and post-transaction beneficial ownership levels but does not provide compensation totals in dollars beyond the withholding price or other company financial metrics.

Hims & Hers Health, Inc. (HIMS) insider filing shows Chief Legal Officer Soleil Boughton reported RSU vesting and related withholding on 09/15/2025. The filing records 41,420 RSUs vested (reported as acquired) and 22,829 shares withheld by the issuer at $53.96 to satisfy tax obligations, leaving 169,041 shares beneficially owned after the transactions. Multiple classes of service-based RSUs vested or were reported as vested with specific quarterly vesting schedules; the filing explains these RSUs convert one-for-one into Class A common shares. The form is signed by an attorney-in-fact on behalf of the reporting person.

Insider transaction summary for HIMS: The Form 4 shows Irene Becklund had multiple equity events on 09/15/2025. Non-derivative entries report 17,983 shares added, resulting in 18,695 shares beneficially owned, and 8,867 shares withheld at a price of $53.96, leaving 9,828 shares after that withholding. Table II reports the vesting/settlement of several restricted stock unit grants, with individual RSU vesting amounts of 1,871, 4,019, 2,291, 4,065, 4,345, and 1,392 RSUs, and aggregate post-transaction share counts listed per line. The filing is signed by an attorney-in-fact on behalf of Ms. Becklund.

Michael Chi, Chief Commercial Officer of Hims & Hers Health, Inc. (HIMS), reported multiple equity transactions on 09/15/2025 executed pursuant to a Rule 10b5-1 trading plan adopted March 4, 2025. The Form 4 shows option exercises and RSU vesting events, plus a sale and shares withheld for taxes. Reported activity includes option exercises at exercise prices of $11.53, $6.82 and $5.01, a sale of 4,150 Class A shares at $56 each, and withholding of 39,872 shares to cover tax obligations. The final line reports 310,888 shares of Class A common stock beneficially owned following the transactions. The Form 4 was signed by an attorney-in-fact on 09/17/2025.

Andrew Dudum, Director and CEO of Hims & Hers Health, Inc. (HIMS), reported multiple equity transactions on Form 4 dated 09/15-09/16/2025. The filing shows vesting and settlement of Restricted Stock Units (RSUs) and exercises of stock options at an exercise price of $2.43, with contemporaneous sales of shares at weighted average prices in the low-$50s. Several share-withholdings covered tax obligations. The reporting person used a Rule 10b5-1 trading plan adopted August 28, 2024 to effect option exercises and subsequent share sales. The Form 4 also lists substantial indirect holdings held in various trusts.

Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc. (HIMS), reported multiple equity transactions dated 09/15/2025. The filing shows settlement/vesting of restricted stock units and the exercise of stock options, followed by share sales. The issuer withheld 58,021 shares to cover tax withholding on vested RSUs. The reporting person exercised 110,000 stock options at an exercise price of $5.01. Subsequent sales included 117,792 shares at a weighted average price of $55.2503 and 27,208 shares at a weighted average price of $55.7936. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted May 21, 2025.